View in EDS

A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational immune profiling.

Saved in:
Bibliographic Details
Title: A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational immune profiling.
Authors: Horvat NK; Department of Hematology & Medical Oncology, Emory University, Atlanta, USA., Diab M; Department of Internal Medicine, Henry Ford Hospital, Detroit, USA. Electronic address: diab.maria@gmail.com., Phillips MJ; Department of Hematology & Medical Oncology, Emory University, Atlanta, USA. Electronic address: maggie.jade.phillips@emory.edu., McCook-Veal A; Winship Cancer Institute of Emory University, Atlanta, USA. Electronic address: ashley.a.mccook@emory.edu., Grundy EE; Department of Hematology & Medical Oncology, Emory University, Atlanta, USA. Electronic address: erin.grundy@emory.edu., Alese OB; Department of Hematology & Medical Oncology, Emory University, Atlanta, USA. Electronic address: olatunji.alese@emory.edu., Greene E; Department of Hematology & Medical Oncology, Emory University, Atlanta, USA. Electronic address: emily.greene@emory.edu., Gbolahan O; Department of Hematology & Medical Oncology, Emory University, Atlanta, USA. Electronic address: ogbolah@emory.edu., Coleman K; Winship Cancer Institute of Emory University, Atlanta, USA. Electronic address: kathleen.marie.coleman@emory.edu., Doxie D; Winship Cancer Institute of Emory University, Atlanta, USA. Electronic address: deon.bryant.doxie@emory.edu., Herting CJ; Department of Hematology & Medical Oncology, Emory University, Atlanta, USA. Electronic address: cameron.herting@gmail.com., Hammons J; Department of Hematology & Medical Oncology, Emory University, Atlanta, USA. Electronic address: jacklyn.nicole.hammons@emory.edu., Mahdi Z; Department of Pathology, Emory University, Atlanta, USA. Electronic address: zaid.mahdi@icloud.com., Switchenko JM; Department of Biostatistics & Bioinformatics, Emory University, Atlanta, USA. Electronic address: jeffrey.switchenko@emory.edu., Paulos CM; Department of Surgery, Emory University, Atlanta, USA; Department of Microbiology and Immunology, Emory University, Atlanta, USA. Electronic address: chrystal.mary.paulos@emory.edu., El-Rayes BF; Department of Medicine, University of Alabama at Birmingham, O'Neal Comprehensive Cancer Center, Birmingham, USA. Electronic address: belrayes@uab.edu., Lesinski GB; Department of Hematology & Medical Oncology, Emory University, Atlanta, USA. Electronic address: gregory.b.lesinski@emory.edu.
Source: Cancer letters [Cancer Lett] 2026 Feb 28; Vol. 639, pp. 218233. Date of Electronic Publication: 2025 Dec 23.
Publication Type: Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II
Journal Info: Publisher: Elsevier Science Ireland Country of Publication: Ireland NLM ID: 7600053 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-7980 (Electronic) Linking ISSN: 03043835 NLM ISO Abbreviation: Cancer Lett Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41448449
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational immune profiling.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Horvat+NK%22">Horvat NK</searchLink>; Department of Hematology & Medical Oncology, Emory University, Atlanta, USA.<br /><searchLink fieldCode="AU" term="%22Diab+M%22">Diab M</searchLink>; Department of Internal Medicine, Henry Ford Hospital, Detroit, USA. Electronic address: diab.maria@gmail.com.<br /><searchLink fieldCode="AU" term="%22Phillips+MJ%22">Phillips MJ</searchLink>; Department of Hematology & Medical Oncology, Emory University, Atlanta, USA. Electronic address: maggie.jade.phillips@emory.edu.<br /><searchLink fieldCode="AU" term="%22McCook-Veal+A%22">McCook-Veal A</searchLink>; Winship Cancer Institute of Emory University, Atlanta, USA. Electronic address: ashley.a.mccook@emory.edu.<br /><searchLink fieldCode="AU" term="%22Grundy+EE%22">Grundy EE</searchLink>; Department of Hematology & Medical Oncology, Emory University, Atlanta, USA. Electronic address: erin.grundy@emory.edu.<br /><searchLink fieldCode="AU" term="%22Alese+OB%22">Alese OB</searchLink>; Department of Hematology & Medical Oncology, Emory University, Atlanta, USA. Electronic address: olatunji.alese@emory.edu.<br /><searchLink fieldCode="AU" term="%22Greene+E%22">Greene E</searchLink>; Department of Hematology & Medical Oncology, Emory University, Atlanta, USA. Electronic address: emily.greene@emory.edu.<br /><searchLink fieldCode="AU" term="%22Gbolahan+O%22">Gbolahan O</searchLink>; Department of Hematology & Medical Oncology, Emory University, Atlanta, USA. Electronic address: ogbolah@emory.edu.<br /><searchLink fieldCode="AU" term="%22Coleman+K%22">Coleman K</searchLink>; Winship Cancer Institute of Emory University, Atlanta, USA. Electronic address: kathleen.marie.coleman@emory.edu.<br /><searchLink fieldCode="AU" term="%22Doxie+D%22">Doxie D</searchLink>; Winship Cancer Institute of Emory University, Atlanta, USA. Electronic address: deon.bryant.doxie@emory.edu.<br /><searchLink fieldCode="AU" term="%22Herting+CJ%22">Herting CJ</searchLink>; Department of Hematology & Medical Oncology, Emory University, Atlanta, USA. Electronic address: cameron.herting@gmail.com.<br /><searchLink fieldCode="AU" term="%22Hammons+J%22">Hammons J</searchLink>; Department of Hematology & Medical Oncology, Emory University, Atlanta, USA. Electronic address: jacklyn.nicole.hammons@emory.edu.<br /><searchLink fieldCode="AU" term="%22Mahdi+Z%22">Mahdi Z</searchLink>; Department of Pathology, Emory University, Atlanta, USA. Electronic address: zaid.mahdi@icloud.com.<br /><searchLink fieldCode="AU" term="%22Switchenko+JM%22">Switchenko JM</searchLink>; Department of Biostatistics & Bioinformatics, Emory University, Atlanta, USA. Electronic address: jeffrey.switchenko@emory.edu.<br /><searchLink fieldCode="AU" term="%22Paulos+CM%22">Paulos CM</searchLink>; Department of Surgery, Emory University, Atlanta, USA; Department of Microbiology and Immunology, Emory University, Atlanta, USA. Electronic address: chrystal.mary.paulos@emory.edu.<br /><searchLink fieldCode="AU" term="%22El-Rayes+BF%22">El-Rayes BF</searchLink>; Department of Medicine, University of Alabama at Birmingham, O'Neal Comprehensive Cancer Center, Birmingham, USA. Electronic address: belrayes@uab.edu.<br /><searchLink fieldCode="AU" term="%22Lesinski+GB%22">Lesinski GB</searchLink>; Department of Hematology & Medical Oncology, Emory University, Atlanta, USA. Electronic address: gregory.b.lesinski@emory.edu.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%227600053%22">Cancer letters</searchLink> [Cancer Lett] 2026 Feb 28; Vol. 639, pp. 218233. <i>Date of Electronic Publication: </i>2025 Dec 23.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Science+Ireland%22">Elsevier Science Ireland </searchLink><i>Country of Publication: </i>Ireland <i>NLM ID: </i>7600053 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1872-7980 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203043835%22">03043835 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Lett <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41448449
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.canlet.2025.218233
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 218233
    Titles:
      – TitleFull: A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational immune profiling.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Horvat NK
      – PersonEntity:
          Name:
            NameFull: Diab M
      – PersonEntity:
          Name:
            NameFull: Phillips MJ
      – PersonEntity:
          Name:
            NameFull: McCook-Veal A
      – PersonEntity:
          Name:
            NameFull: Grundy EE
      – PersonEntity:
          Name:
            NameFull: Alese OB
      – PersonEntity:
          Name:
            NameFull: Greene E
      – PersonEntity:
          Name:
            NameFull: Gbolahan O
      – PersonEntity:
          Name:
            NameFull: Coleman K
      – PersonEntity:
          Name:
            NameFull: Doxie D
      – PersonEntity:
          Name:
            NameFull: Herting CJ
      – PersonEntity:
          Name:
            NameFull: Hammons J
      – PersonEntity:
          Name:
            NameFull: Mahdi Z
      – PersonEntity:
          Name:
            NameFull: Switchenko JM
      – PersonEntity:
          Name:
            NameFull: Paulos CM
      – PersonEntity:
          Name:
            NameFull: El-Rayes BF
      – PersonEntity:
          Name:
            NameFull: Lesinski GB
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 28
              M: 02
              Text: 2026 Feb 28
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1872-7980
          Numbering:
            – Type: volume
              Value: 639
          Titles:
            – TitleFull: Cancer letters
              Type: main
ResultId 1